ANTIMICROBIAL ACTIVITY IN URINE AND CLINICAL EFFICACY OF CEFTIZOXIME

• Published in: CHEMOTHERAPY Vol. 28; no. Supplement5; pp. 696 - 705
• Main Authors: SHIMAZU, RYOICHI, KATO, NAOKI, BAN, YOSHIHITO, KAWADA, YUKIMICHI, NISHIURA, TSUNEO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1980
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.28.Supplement5_696

Ceftizoxime, a new cephalosporin derivative for parenteral use, was studied both bacteriologically and clinically and following conclusions were obtained. 1) Ceftizoxime showed stronger antimicrobial activity against E. coli, Klebsiella and Serratia than cefazolin. 2) The peak serum levels of 127.3, 63.9 and 25.9 μg/ml were achieved 5 minutes after intravenous injection of 1 g, 0.5 g or 0.25 g of ceftizoxime, and they were dose-dependent. 3) The peak urinary levels of 4, 630, 1, 424 and 585 μg/ml of ceftizoxime were achieved within 2 hours after intravenous injection of the same doses. 4) Antimicrobial activity in urine excreted after administration of ceftizoxime against E. coli, Klebsiella and Serratia was stronger than that of cefazolin. 5) Seven cases with chronic complicated urinary tract infections were treated with ceftizoxime and excellent or moderate responses were obtained in 5 cases. 6) No significant side effects were observed in any of the 7 cases. 7) In conclusion, ceftizoxime was regarded as effective and safe drug in the treatment of urinary tract infections.